Meyka Pro banner
Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc (KNSA) Stock Competitors & Peer Comparison

See (KNSA) competitors and their performances in Stock Market.

KNSANASDAQ
HealthcareMedical - Pharmaceuticals
$63.17
$0.78(1.21%)
U.S. Market is Open · 12:52

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
KNSA$63.95+4.65%4.8B71.06$0.90N/A
RPRX$58.18-0.60%25B11.48$5.07+1.56%
WBA$11.98+0.50%10.4B-1.64-$7.29+4.17%
CORT$90.52+0.89%9.7B258.63$0.35N/A
LQDA$79.94+6.20%7.1B571.00$0.14N/A
VCRE$11.82+1.03%3.3BN/AN/AN/A
TRLV$8.79+4.52%1.5B-20.88-$0.42N/A
HROWL$25.61+0.19%1.4BN/AN/AN/A
HROWM$26.03-0.08%1.3BN/AN/AN/A
AVLN$28.30+10.20%1.3B-1.30-$21.83N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

KNSA vs RPRX Comparison July 2026

KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 4.8B. In comparison, RPRX has a market cap of 25B. Regarding current trading prices, KNSA is priced at $63.95, while RPRX trades at $58.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 71.06, whereas RPRX's P/E ratio is 11.48. In terms of profitability, KNSA's ROE is +0.13%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, KNSA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check RPRX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions